Cardiovascular DiseasesAIRCARDNCT04353232
Impact of Lifetime Exposure to Air and Noise Pollution on Cardiovascular Disease and Mortality - the AIRCARD Study.
An observational study of Cardiovascular Diseases and Particulate Matter Inhalation Injury, run by Odense University Hospital at 1 site in Denmark.
Trial summary
The purpose of this study is to determine the impact of individually lifetime accumulated exposure to air and noise pollution on the incidence and prevalence of cardiovascular diseases (CVD) and mortality. Air as well as noise pollution have harmful effects on human health. Read more about this study
- Who is it for?
- Ages 60 to 74 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Cardiovascular Diseases, Particulate Matter Inhalation Injury, Arteriosclerosis
- How many people
- 33,723 participants
- Where
- 1 siteDenmark
- Study dates
- 2 Jan 2020to 1 Sep 2026
- How long will I take part?
- 10 Years
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 60 to 74 years
- Men only
- Healthy volunteers accepted
- Adult, Older adult
Study population: Men aged 60-74 from DANCAVAS and VIVA trials
Who may be able to join
- male gender, age between 60-74 years living on the Island of Funen, or in the surrounding communities of Vejle, Silkeborg and Nykøbing Falster.
- male gender, age between 65-74 years living in the region of Mid Denmark (Viborg County).
Who cannot join
- There were no exclusion criteria.
- VIVA study
- There were no exclusion criteria.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Air and Noise Pollution Exposure and Cardiovascular Disease in Danish Males Aged 60-74 From DANCAVAS and VIVA: A Population-Based Study.
The purpose of this study is to determine the impact of individually lifetime accumulated exposure to air and noise pollution on the incidence and prevalence of cardiovascular diseases (CVD) and mortality.
Air as well as noise pollution have harmful effects on human health. Experimental and clinical studies have shown a strong impact between particulate matter (PM2.5) and cardiovascular disease (CVD). Prolonged exposure to PM2.5 has been associated with the development of atherosclerosis and adverse cardiovascular events. However, also short-term exposure has been linked to acute coronary events. PM2.5 is, however, a combination of many components of specific pollutants that have a size of two and a half microns or less in width. However, there is a knowledge gap, as investigation into which specific components of air pollutants that contribute the most to the development of CVD is lacking. There is a need to adopt and encourage preventive measures but also put in place environmental policies that are effective in promoting the reduction of exposure to pollutants. We want to aid in this shift by showing which specific pollutants contribute the most to the development of CVD so that we can better target these specific air pollutants for better prevention initiatives.
Read the detailed description
The purpose of this study is to determine the impact of individually accumulated exposure to air and noise pollution, as well as exposure fluctuations (peaks), on the incidence and prevalence of CVD. Noise pollution can be a significant confounder for the relation investigated and we will therefore include accumulated data for noise over time together with air pollution data.
The ICD or SKS disease classification code system will be used to identify clinical events for patients from the two trials (described below). CVD mortality and total mortality as well as clinical events from myocardial infarctions, percutaneous coronary interventions, coronary artery bypass grafts, heart failure, apoplexies, and bypass will be examined. The analysis will be stratified by socioeconomic status to determine if there is a social inequality in the air and noise pollution impact.
We will examine the individual air pollution exposure as well as noise exposure to understand each pollutants' contribution to the accumulated risk and demonstrate the impact of air and noise pollution on CVD morbidity and mortality. We hypothesize that:
- the amount of accumulated air as well as noise pollution is a highly independent significant risk factor for clinical CVD, when accounting for all traditional cardiovascular risk factors.
- certain subdivisions of the air pollution exposure carry the highest contribution for development of clinical CVD. This will provide novel and valuable information as this has never been investigated with the precision we can deliver.
- accumulated air and noise pollution from both individual home addresses and work addresses together better predicts clinical CVD than models based solely on home addresses. No study has evaluated this before.
Furthermore, the impact on the result of social inequality will be thoroughly examined.
This study is designed as a prospective registry-based observational study using modelled air/noise pollution data. The population is predominantly males from two Danish clinical trials (DANCAVAS and VIVA trials)
DANCAVAS I and II are two similar population-based randomized, multicentered, clinically controlled studies designed to evaluate the benefits of 7-step multiple cardiovascular screening and modern vascular prophylaxis in a population of men and a small subpopulation of females, aged 60-74 years, living in the southern part of Denmark. For each participant, all relevant CVD risk factors were measured or determined.
The screening included: 1) low-dose non-contrast CT scan to detect CAC and aortic/iliac aneurysms, 2) ankle-brachial blood pressure index (ABI) to detect peripheral arterial disease (PAD) and hypertension, 3) a telemetric assessment of the heart rhythm, and 4) a measurement of the cholesterol and plasma glucose levels.
The Viborg Vascular (VIVA) screening trial (44) is a randomized, multicentered, population-based clinically controlled study designed to evaluate the benefits of vascular screening and modern vascular prophylaxis in men between 65-74 years of age living in the region of Mid Denmark (Viborg County). For each participant, abdominal ultrasound scanning of the infrarenal aorta were performed to detect abdominal aortic aneurism (AAA), and ABI were measured to detect PAD and hypertension. In all, 18,749 men were screened.
A total of 33,723 participants in the age of 60-74 are included from the two cohorts. In both trials, an AAA was defined as maximal infrarenal diameter of 30 mm or more, and PAD was defined as an ABI < 0.90 or >=1.40 using the same validated hand held Doppler-based methodology (46). We have accounted for traditional CVD confounders in all participants. This is unique for our study. Previous studies on air pollution and CVD burden have not been able to prospectively consider these confounding variables to the same extent.
In Denmark a validated and reliable air pollution model system is available. The system is named DEHM/UBM/AirGIS and consists of three coupled models; the Danish Eulerian Hemispheric Model (DEHM), the Urban Background Model (UBM) and the Operational Street Pollution Model (OSPM) and a GIS system (AirGIS) that couples the modelled concentrations with the address level of the population. The system calculates air pollution concentrations of 80 chemical species as well as air pollution levels in cities, in streets and on address level even on both side of the street. These pollution levels can be calculated back to 1979 giving retrospectively data 40 years back. The model system is validated in relation to air pollution measurements throughout Denmark back to 1990 with high correlation between model estimated values and measured values. This multi-scale model system is unique, capable of running on very high temporal (hourly) and spatial (address level) resolutions. The development of the models and the calculation of air pollution and measurements is performed at Aarhus University, Department of Environmental Science (ENVS). The model is robust; taking all necessary factors into account that could contribute to the individual life-long air pollution exposure and the model is one of the best in the world.
Noise is calculated using state-of-the-art algorithms implemented in a well-known software, the SoundPLAN. The algorithms, reflecting advanced physics and mathematics-based knowledge, consider the propagation of sound in the atmosphere as well as the sound originating from the source, e.g., road transport, railway. Here, information from various national registers, such as the national traffic database, including traffic counts, travel speeds, the building register, the address register, and the Danish surface and elevation model, to name a few. In addition, advanced weather classes reflecting all meteorological conditions in Denmark are used in noise calculations. The model output is a noise estimate at the address location or any location of interest in Denmark, which can be subsequently used to investigate the health impacts of short-term and/or long-term noise exposure.
The entire study population is monitored until December 31. 2022, in the Danish national registers.
Primarily, a multivariate Cox proportional hazards regression model will be used to examine the associations between air- and noise pollution and all-cause mortality and CVD morbidity and mortality when adjusting for inclusion date, sex, and other potential confounding factors at baseline.
Descriptive statistics of the main study variables to examine noise pollution will be presented in tables, frequencies with percentages of dichotomous/ordinal variables and medians with quartiles for numeric variables. Outcomes will be analyzed both as dichotomized variables, present CAC, severe CAC (CAC score above 400), AAA and PAD, and as the underlying continuous variables, CAC score, aortic diameter, and lowest measured ankle-brachial blood pressure index. Confounding CVD variables will be considered and adjusted for (e.g., lifestyle, medical history, QoL, weight, height, waist circumference, blood pressure, ABI, calcium score for coronary arteries, aortic dimensions, HbA1c and lipid parameters).
To investigate hypothesis about noise we will, for each dichotomized outcome, estimate adjusted odds ratios using multivariable logistic regression, with cumulated noise pollution as exposure and the Framingham risk factors as confounders. The continuous variables will be analyzed in multivariable linear regression models and the cardiovascular risk factors as confounders.
To investigate the impact of work versus home address, we will compare regression models with accumulated air pollution from both work and home addresses with models with air pollution only from home addresses. ROC curves from both models will be compared to evaluate the hypothesis.
- Conditions
- Cardiovascular Diseases, Particulate Matter Inhalation Injury, Arteriosclerosis, Pollution; Exposure
- Keywords
- Air Pollution, Environmental Exposure, DANCAVAS, VIVA, DEHM/UBN/AirGIS, Noise Pollution
- Medical subject headings
- Cardiovascular Diseases, Arteriosclerosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| DANCAVAS trial | We performed a population-based, parallel-group, randomized, controlled trial involving men 65 to 74 years of age living in 15 Danish municipalities. The participants were randomly assigned in a 1:2 ratio to undergo screening (the invited group) or not to undergo screening (the control group) for subclinical cardiovascular disease. Randomization was based on computer-generated random numbers and stratified according to municipality. A total of 46,611 participants underwent randomization. After exclusion of 85 men who had died or emigrated before being invited to undergo screening, there were 16,736 men in the invited group and 29,790 men in the control group; 10,471 of the men in the invited group underwent screening (62.6%). In intention-to-treat analyses, after a median follow-up of 5.6 years, 2106 men (12.6%) in the invited group and 3915 men (13.1%) in the control group had died. | |
| VIVA trial | In this randomised controlled trial, we randomly allocated (1:1) all men aged 65-74 years living in the Central Denmark Region to screening for abdominal aortic aneurysm, peripheral arterial disease, and hypertension, or to no screening. We based allocation on computer-generated random numbers from 1 to 100 in blocks of 1067 to 4392, stratified by 19 municipalities. Only the non-screening group and the investigator assessing outcomes were masked. We invited participants who were found to have abdominal aortic aneurysm or peripheral arterial disease back for confirmation and eventual initiation of relevant pharmacological therapy. We further offered participants with abdominal aortic aneurysm annual control or surgical repair. We referred participants with suspected hypertension to their general practitioner. The primary outcome was all-cause mortality, assessed 5 years after randomisation. This trial is registered at ClinicalTrials.gov, number NCT00662480. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Subclinical and Clinical CVD events, CVD-specific mortality, all-cause mortality
The amount of accumulated air as well as noise pollution as an independent significant risk factor for clinical CVD and mortality, when accounting for all traditional cardiovascular risk factors.
Measured: 40 years
Maximal infrarenal aortic diameter in mm and presence of abdominal aortic Aneurisme (Yes/N0)
Aortic abdominal aneurism
Measured: 40 years
Coronary artery calcium (CAC)
the total amount of calcium in the coronary artery
Measured: 40 years
Measures of blod pressure on the ankle in mmHg and brachial in mmHg to determined periferal arterial disease (PAD)
lowest measured ankle brachial blood pressure index or presence of PAD
Measured: 40 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Apr 2020
- Study start2 Jan 2020
- Primary completion1 Jan 2022
- Study completion1 Sep 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Cardiovascular DiseasesStudies of the same condition, open and under way.
- More trials run by Odense University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 33,723 participants (actual)
- Target duration
- 10 Years
Sponsor and investigators
- Lead sponsor
- Odense University Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- DANCAVAS Study Group, Department of Environmental Science, Aarhus, Department of Cardiac, Thoracic and Vascular Surgery, Odense University Hospital, Department of Cardiology, Odense University Hospital, Danish Cancer Society
- Responsible party
- Principal investigator, Jess Lambrechtsen, Odense University Hospital
- Investigators
- Stephan P Mayntz, MD, MPH, Principal investigator, Odense University HospitalJess Lambrechtsen, Prof., MD, Principal investigator, Odense University HospitalRoda A Mohamed, MD, Principal investigator, Odense University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04353232
- Sponsor's protocol ID
- AIRCARD
- Acronym
- AIRCARD
- Status last verified
- Oct 2023
- First submitted
- 15 Apr 2020
- Last updated
- 24 Oct 2023
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Mayntz SP, Mohamed RA, Mejldal A, Moller JK, Lindholt JS, Diederichsen AC, Frohn LM, Brandt J, Ketzel M, Khan J, Lambrechtsen J. Long-Term Road Traffic Noise, Air Pollution, and Cardiovascular Disease: AIRCARD: A Prospective Cohort Study. JACC Adv. 2025 Jun;4(6 Pt 1):101787. doi: 10.1016/j.jacadv.2025.101787. Epub 2025 May 21.
PubMed 40403531Mayntz SP, Mohamed RA, Mejldal A, Moller JK, Lindholt JS, Diederichsen ACP, Frohn LM, Lambrechtsen J. Statistical Analysis Plan for the AIRCARD Study: Individual Long-Term Air and Noise Pollution Exposure and Cardiovascular Disease Incidence and Mortality - A Prospective Cohort Study Utilizing DANCAVAS and VIVA Screening Trials. Cardiology. 2025;150(1):56-62. doi: 10.1159/000539459. Epub 2024 Jul 17.
PubMed 38952116
Study at a glance
From the registry record, last updated by the sponsor on 24 Oct 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Air and Noise Pollution Exposure and Cardiovascular Disease in Danish Males Aged 60-74 From DANCAVAS and VIVA: A Population-Based Study.
- ClinicalTrials.gov ID
- NCT04353232
- Acronym / sponsor ID
- AIRCARD / AIRCARD
- Conditions
- Cardiovascular Diseases, Particulate Matter Inhalation Injury, Arteriosclerosis, Pollution; Exposure
- Keywords
- Air Pollution, Environmental Exposure, DANCAVAS, VIVA, DEHM/UBN/AirGIS, Noise Pollution
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 33,723 participants (actual)
- Lead sponsor
- Odense University HospitalUniversity, hospital or other
- Collaborators
- DANCAVAS Study Group, Department of Environmental Science, Aarhus, Department of Cardiac, Thoracic and Vascular Surgery, Odense University Hospital, Department of Cardiology, Odense University Hospital, Danish Cancer Society
- Study start
- 2 Jan 2020 (actual)
- Primary completion
- 1 Jan 2022 (actual)
- Study completion
- 1 Sep 2026 (estimated)
- First posted
- 20 Apr 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to determine the impact of individually lifetime accumulated exposure to air and noise pollution on the incidence and prevalence of cardiovascular diseases (CVD) and mortality.
Air as well as noise pollution have harmful effects on human health. Experimental and clinical studies have shown a strong impact between particulate matter (PM2.5) and cardiovascular disease (CVD). Prolonged exposure to PM2.5 has been associated with the development of atherosclerosis and adverse cardiovascular events. However, also short-term exposure has been linked to acute coronary events. PM2.5 is, however, a combination of many components of specific pollutants that have a size of two and a half microns or less in width. However, there is a knowledge gap, as investigation into which specific components of air pollutants that contribute the most to the development of CVD is lacking. There is a need to adopt and encourage preventive measures but also put in place environmental policies that are effective in promoting the reduction of exposure to pollutants. We want to aid in this shift by showing which specific pollutants contribute the most to the development of CVD so that we can better target these specific air pollutants for better prevention initiatives.
Detailed description
The purpose of this study is to determine the impact of individually accumulated exposure to air and noise pollution, as well as exposure fluctuations (peaks), on the incidence and prevalence of CVD. Noise pollution can be a significant confounder for the relation investigated and we will therefore include accumulated data for noise over time together with air pollution data.
The ICD or SKS disease classification code system will be used to identify clinical events for patients from the two trials (described below). CVD mortality and total mortality as well as clinical events from myocardial infarctions, percutaneous coronary interventions, coronary artery bypass grafts, heart failure, apoplexies, and bypass will be examined. The analysis will be stratified by socioeconomic status to determine if there is a social inequality in the air and noise pollution impact.
We will examine the individual air pollution exposure as well as noise exposure to understand each pollutants' contribution to the accumulated risk and demonstrate the impact of air and noise pollution on CVD morbidity and mortality. We hypothesize that:
- the amount of accumulated air as well as noise pollution is a highly independent significant risk factor for clinical CVD, when accounting for all traditional cardiovascular risk factors.
- certain subdivisions of the air pollution exposure carry the highest contribution for development of clinical CVD. This will provide novel and valuable information as this has never been investigated with the precision we can deliver.
- accumulated air and noise pollution from both individual home addresses and work addresses together better predicts clinical CVD than models based solely on home addresses. No study has evaluated this before.
Furthermore, the impact on the result of social inequality will be thoroughly examined.
This study is designed as a prospective registry-based observational study using modelled air/noise pollution data. The population is predominantly males from two Danish clinical trials (DANCAVAS and VIVA trials)
DANCAVAS I and II are two similar population-based randomized, multicentered, clinically controlled studies designed to evaluate the benefits of 7-step multiple cardiovascular screening and modern vascular prophylaxis in a population of men and a small subpopulation of females, aged 60-74 years, living in the southern part of Denmark. For each participant, all relevant CVD risk factors were measured or determined.
The screening included: 1) low-dose non-contrast CT scan to detect CAC and aortic/iliac aneurysms, 2) ankle-brachial blood pressure index (ABI) to detect peripheral arterial disease (PAD) and hypertension, 3) a telemetric assessment of the heart rhythm, and 4) a measurement of the cholesterol and plasma glucose levels.
The Viborg Vascular (VIVA) screening trial (44) is a randomized, multicentered, population-based clinically controlled study designed to evaluate the benefits of vascular screening and modern vascular prophylaxis in men between 65-74 years of age living in the region of Mid Denmark (Viborg County). For each participant, abdominal ultrasound scanning of the infrarenal aorta were performed to detect abdominal aortic aneurism (AAA), and ABI were measured to detect PAD and hypertension. In all, 18,749 men were screened.
A total of 33,723 participants in the age of 60-74 are included from the two cohorts. In both trials, an AAA was defined as maximal infrarenal diameter of 30 mm or more, and PAD was defined as an ABI < 0.90 or >=1.40 using the same validated hand held Doppler-based methodology (46). We have accounted for traditional CVD confounders in all participants. This is unique for our study. Previous studies on air pollution and CVD burden have not been able to prospectively consider these confounding variables to the same extent.
In Denmark a validated and reliable air pollution model system is available. The system is named DEHM/UBM/AirGIS and consists of three coupled models; the Danish Eulerian Hemispheric Model (DEHM), the Urban Background Model (UBM) and the Operational Street Pollution Model (OSPM) and a GIS system (AirGIS) that couples the modelled concentrations with the address level of the population. The system calculates air pollution concentrations of 80 chemical species as well as air pollution levels in cities, in streets and on address level even on both side of the street. These pollution levels can be calculated back to 1979 giving retrospectively data 40 years back. The model system is validated in relation to air pollution measurements throughout Denmark back to 1990 with high correlation between model estimated values and measured values. This multi-scale model system is unique, capable of running on very high temporal (hourly) and spatial (address level) resolutions. The development of the models and the calculation of air pollution and measurements is performed at Aarhus University, Department of Environmental Science (ENVS). The model is robust; taking all necessary factors into account that could contribute to the individual life-long air pollution exposure and the model is one of the best in the world.
Noise is calculated using state-of-the-art algorithms implemented in a well-known software, the SoundPLAN. The algorithms, reflecting advanced physics and mathematics-based knowledge, consider the propagation of sound in the atmosphere as well as the sound originating from the source, e.g., road transport, railway. Here, information from various national registers, such as the national traffic database, including traffic counts, travel speeds, the building register, the address register, and the Danish surface and elevation model, to name a few. In addition, advanced weather classes reflecting all meteorological conditions in Denmark are used in noise calculations. The model output is a noise estimate at the address location or any location of interest in Denmark, which can be subsequently used to investigate the health impacts of short-term and/or long-term noise exposure.
The entire study population is monitored until December 31. 2022, in the Danish national registers.
Primarily, a multivariate Cox proportional hazards regression model will be used to examine the associations between air- and noise pollution and all-cause mortality and CVD morbidity and mortality when adjusting for inclusion date, sex, and other potential confounding factors at baseline.
Descriptive statistics of the main study variables to examine noise pollution will be presented in tables, frequencies with percentages of dichotomous/ordinal variables and medians with quartiles for numeric variables. Outcomes will be analyzed both as dichotomized variables, present CAC, severe CAC (CAC score above 400), AAA and PAD, and as the underlying continuous variables, CAC score, aortic diameter, and lowest measured ankle-brachial blood pressure index. Confounding CVD variables will be considered and adjusted for (e.g., lifestyle, medical history, QoL, weight, height, waist circumference, blood pressure, ABI, calcium score for coronary arteries, aortic dimensions, HbA1c and lipid parameters).
To investigate hypothesis about noise we will, for each dichotomized outcome, estimate adjusted odds ratios using multivariable logistic regression, with cumulated noise pollution as exposure and the Framingham risk factors as confounders. The continuous variables will be analyzed in multivariable linear regression models and the cardiovascular risk factors as confounders.
To investigate the impact of work versus home address, we will compare regression models with accumulated air pollution from both work and home addresses with models with air pollution only from home addresses. ROC curves from both models will be compared to evaluate the hypothesis.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 10 Years
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| DANCAVAS trial | – | –We performed a population-based, parallel-group, randomized, controlled trial involving men 65 to 74 years of age living in 15 Danish municipalities. The participants were randomly assigned in a 1:2 ratio to undergo screening (the invited group) or not to undergo screening (the control group) for subclinical cardiovascular disease. Randomization was based on computer-generated random numbers and stratified according to municipality. A total of 46,611 participants underwent randomization. After exclusion of 85 men who had died or emigrated before being invited to undergo screening, there were 16,736 men in the invited group and 29,790 men in the control group; 10,471 of the men in the invited group underwent screening (62.6%). In intention-to-treat analyses, after a median follow-up of 5.6 years, 2106 men (12.6%) in the invited group and 3915 men (13.1%) in the control group had died. |
| VIVA trial | – | –In this randomised controlled trial, we randomly allocated (1:1) all men aged 65-74 years living in the Central Denmark Region to screening for abdominal aortic aneurysm, peripheral arterial disease, and hypertension, or to no screening. We based allocation on computer-generated random numbers from 1 to 100 in blocks of 1067 to 4392, stratified by 19 municipalities. Only the non-screening group and the investigator assessing outcomes were masked. We invited participants who were found to have abdominal aortic aneurysm or peripheral arterial disease back for confirmation and eventual initiation of relevant pharmacological therapy. We further offered participants with abdominal aortic aneurysm annual control or surgical repair. We referred participants with suspected hypertension to their general practitioner. The primary outcome was all-cause mortality, assessed 5 years after randomisation. This trial is registered at ClinicalTrials.gov, number NCT00662480. |
Who may qualify
- Ages
- 60 to 74 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Men aged 60-74 from DANCAVAS and VIVA trials
Key inclusion criteria (2 listed)
- male gender, age between 60-74 years living on the Island of Funen, or in the surrounding communities of Vejle, Silkeborg and Nykøbing Falster.
- male gender, age between 65-74 years living in the region of Mid Denmark (Viborg County).
Key exclusion criteria (3 listed)
- There were no exclusion criteria.
- VIVA study
- There were no exclusion criteria.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Subclinical and Clinical CVD events, CVD-specific mortality, all-cause mortality
Time frame: 40 years
The amount of accumulated air as well as noise pollution as an independent significant risk factor for clinical CVD and mortality, when accounting for all traditional cardiovascular risk factors.
Maximal infrarenal aortic diameter in mm and presence of abdominal aortic Aneurisme (Yes/N0)
Time frame: 40 years
Aortic abdominal aneurism
Coronary artery calcium (CAC)
Time frame: 40 years
the total amount of calcium in the coronary artery
Measures of blod pressure on the ankle in mmHg and brachial in mmHg to determined periferal arterial disease (PAD)
Time frame: 40 years
lowest measured ankle brachial blood pressure index or presence of PAD
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Oct 2023.
- Derived from this study: PubMed 40403531Mayntz SP, Mohamed RA, Mejldal A, Moller JK, Lindholt JS, Diederichsen AC, Frohn LM, Brandt J, Ketzel M, Khan J, Lambrechtsen J. Long-Term Road Traffic Noise, Air Pollution, and Cardiovascular Disease: AIRCARD: A Prospective Cohort Study. JACC Adv. 2025 Jun;4(6 Pt 1):101787. doi: 10.1016/j.jacadv.2025.101787. Epub 2025 May 21.
- Derived from this study: PubMed 38952116Mayntz SP, Mohamed RA, Mejldal A, Moller JK, Lindholt JS, Diederichsen ACP, Frohn LM, Lambrechtsen J. Statistical Analysis Plan for the AIRCARD Study: Individual Long-Term Air and Noise Pollution Exposure and Cardiovascular Disease Incidence and Mortality - A Prospective Cohort Study Utilizing DANCAVAS and VIVA Screening Trials. Cardiology. 2025;150(1):56-62. doi: 10.1159/000539459. Epub 2024 Jul 17.
- Individual participant dataSharing planned: Undecided
Related trials for Cardiovascular Diseases
Active, not recruitingPhase 3
ENDOTHELION Study Group: Effect of Bosentan in NAION Patients
Ischemic Optic Neuropathy
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Not yet recruitingPhase 2
Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma (RRMM)
RecruitingPhase 2
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
Multiple Myeloma
Recruiting
PAW-Hydrogel for Chronic Wound Healing
Diabetic Foot Ulcer (DFU), Pressure Ulcer (PU)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Stephan P Mayntz, MD, MPH principal investigator
Odense University Hospital
Jess Lambrechtsen, Prof., MD principal investigator
Odense University Hospital
Roda A Mohamed, MD principal investigator
Odense University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cardiovascular Diseases and Particulate Matter Inhalation Injury, run by Odense University Hospital at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 24 Oct 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Subclinical and Clinical CVD events, CVD-specific mortality, all-cause mortality (time frame: 40 years). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04353232, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Oct 2023.